Adam M. Veness, Senior Vice President, General Counsel and Secretary of Dianthus Therapeutics, Inc. (NASDAQ:DNTH), filed a statement of changes in beneficial ownership on August 14, 2026, reporting a stock option exercise dated August 13, 2026.

Key Highlights

  • Reporting person: Adam M. Veness, SVP, General Counsel and Secretary of Dianthus Therapeutics, Inc.
  • Transaction: Exercise of a stock option (transaction code M) covering 15,000 shares of common stock on August 13, 2026.
  • Exercise price: $18.17 per share, with the derivative security carrying a reported price of $0.
  • Post-transaction ownership: 15,000 shares of common stock held directly; 73,240 stock options (right to buy) remaining, held directly.
  • Option expiration: The underlying stock option is set to expire on June 28, 2033.
  • Vesting schedule: 25% of the option shares vested on June 20, 2024, with the remaining three quarters vesting in equal monthly installments over the following three years, subject to continued service.

Option Exercise Details for Dianthus Therapeutics General Counsel

According to the filing, Adam M. Veness exercised a stock option on August 13, 2026, acquiring 15,000 shares of Dianthus Therapeutics common stock at an exercise price of $18.17 per share. The transaction is recorded under transaction code M in Table I, reflecting an acquisition of common stock through the exercise of a derivative security. Following the transaction, Veness directly holds 15,000 shares of common stock, as reported in the filing.

The filing also discloses activity in Table II covering derivative securities. The stock option exercised carried an exercise price of $18.17 and an expiration date of June 28, 2033. The reported price of the derivative security at the time of exercise was $0. After the transaction, Veness retains 73,240 stock options with the right to buy common stock, held on a direct basis, according to the filing.

Dianthus Therapeutics, Inc. is a Delaware-incorporated company listed on NASDAQ under the symbol DNTH. Veness, whose address of record is listed as c/o Dianthus Therapeutics, Inc., 7 Times Square, 43rd Floor, New York, New York 10036, filed this report individually as a single reporting person. The filing notes that 25% of the shares underlying the option vested on June 20, 2024, with the balance vesting in equal monthly installments over the three years following that date, subject to continued service to the issuer on each vesting date.

What Was Disclosed

The filing reports that Adam M. Veness, in his role as SVP, General Counsel and Secretary at Dianthus Therapeutics, exercised a stock option covering 15,000 shares of common stock on August 13, 2026, at $18.17 per share, retaining 73,240 options afterward.